PLUR Pluri Inc. Return on Sales by Gross Profit

PLUR (Pluri) - company brandmark

Pluri Inc. is developing a bioplatform for the mass cultivation of cells in bioreactors to reduce production costs. The gross margin share on GURU.Markets highlights the efficiency trend, where 16.90 serves as the current parameter value. The company's prospects rely on expansion into the B2B segment and the launch of innovative PLX solutions for regenerative medicine and agrotech.

Pluri (PLUR): Gross Profitability from 04/28/2023 to 11/20/2026

Comprehensive metric breakdowns and analytics for Pluri (PLUR)

- current quotes and average value forecast:
Basic company analysis:Pluri Inc. (PLUR)
Finished products of pluri-biotech.com

The competitiveness of Pluri Inc. (PLUR) is based on high-tech biofabrication, where the implementation of ESG standards in bioreactor operations minimizes resource-related operating expenses. The efficiency of this model is quantified through the share of revenue minus direct costs, allowing investors to assess capital density and avoid overpaying for the asset by tracking annual gross margin trends.